Innovent completes first patient dosing of modular CAR-T cell product
Category: #health  By Pankaj Singh  Date: 2022-02-21
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Innovent completes first patient dosing of modular CAR-T cell product

Innovent Biologics Inc., a top-class biopharma company that manufactures, develops, and promotes high-quality medicines, has reportedly announced the dosing of the first patient for its universal IgG-based modular Claudin 18.2-targeting CAR-T (chimeric antigen receptor T) cell product IBI345.

This product will be used for treating advanced solid tumors that are Claudin 18.2-positive in an IIT (investigator-initiated-trial). Since the company announced its planned cooperation with Roche in June 2020, this is the first revelation of the development breakthrough for cell therapy products based on Roche's licensed innovative tech platform.

The study is a clinical trial initiated by investors with the primary aim of assessing the tolerability, safety, preliminary efficacy, and pharmacokinetics of IBI345 in subjects having Claudin 18.2-positive solid tumors.

CAR-T cell therapy has set a relevant role in treating hematological tumors with five FDA-approved products and two approved by the China-based NMPA. However, the antitumor efficacy of solid tumors is a challenge that calls for technological developments.

Being the first universal CAR-T cell product of the world, IBI345 has possibly differentiated benefits over traditional CAR-T cell therapy products which include:

  • Controlling the CAR-T cell functional activity through simultaneously providing antibodies that link the CAR-T cell and target cell, possibly offering a better safety profile.
  • Using antibody function to focus on tumor antigens and accordingly scaling the tumor antigen signal to navigate CAR-T cells to enter the tumor, thereby helping the initiation of recognizing and killing tumors.
  • Allows for the simultaneous and sequential administration of over one antibody focusing on antigen targets without altering CAR-T cells, to treat tumors with antigen expressed that are highly heterogeneous or relapsed tumors owing to antigen loss thus enhancing the flexibility and increasing the accessibility of CAR-T therapy for patients.

It should be noted that the Claudin protein is a crucial component of complex molecules that play a critical role in the human body’s life activities.

Source credit:

https://www.prnewswire.com/news-releases/innovent-announces-first-patient-dosing-of-universal-modular-car-t-cell-product-ibi345-301486172.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...